Incannex Healthcare Inc. - 8-K Filing

Incannex Healthcare Inc. announces first patient dosed in DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $IXHL

Read the full article at SEC EDGAR

More Regulatory news